>
Soaring Eagle Acquisition logo

SRNGU - Soaring Eagle Acquisition Share Price

$11.97 1.3  12.6%

Sector
Healthcare
Size
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 7261
Bullish
Bearish
Unlock SRNGU Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 01st Jan 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2021, GinkgoBioworks Holdings Inc revenues was not reported. Net losstotaled to $101M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SRNGU Revenue Unlock SRNGU Revenue

Net Income

SRNGU Net Income Unlock SRNGU Revenue

Normalised EPS

SRNGU Normalised EPS Unlock SRNGU Revenue

PE Ratio Range

SRNGU PE Ratio Range Unlock SRNGU Revenue

Dividend Yield Range

SRNGU Dividend Yield Range Unlock SRNGU Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
SRNGU EPS Forecasts Unlock SRNGU Revenue
Profile Summary

Ginkgo Bioworks Holdings, Inc., formerly Spinning Eagle Acquisition Corp, is engaged in building a platform to program cells. The Company's platform is used to program cells on behalf of its customers. Its cell programs are designed to enable biological production of products as therapeutics, key food ingredients, and chemicals derived from petroleum. The Company's platform is used to design, write, and debug deoxyribonucleic acid (DNA) code in engineered organisms to execute programs for its customers. Its platform is used by customers for manufacturing processes or develop new products through biology. The foundation of its platform includes two assets that execute a variety of cell programs for customers according to their specifications: Foundry and Codebase. It serves industries, including chemicals, agriculture, food, consumer products and pharmaceuticals.

Directors
Last Annual January 1st, 1970
Last Interim January 1st, 1970
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Capital Market
Shares in Issue
Free Float (0.0%)
Eligible for
× ISAs
SIPPs
SRNGU Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.